New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
June 21, 2023 07:59 ET
|
Crinetics Pharmaceuticals, Inc.
Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics' Founder & CEO, Scott Struthers Accepted John D. Baxter Prize for Entrepreneurship from ENDO...
Crinetics to Highlight Broad Pipeline at ENDO 2023
June 09, 2023 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the...